Plans to move the near-1,000-foot-long vessel between piers Thursday were scrapped. A new schedule was not provided.
Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback